Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) DeferredTaxAndRevenue: S$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Singapore Institute Of Advanced Medicine Holdings DeferredTaxAndRevenue?

Singapore Institute Of Advanced Medicine Holdings SGX:9G2 DeferredTaxAndRevenue is S$0.00 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Singapore Institute Of Advanced Medicine Holdings's current deferred tax and revenue for the quarter that ended in Jun. 2026 was S$0.00 Mil.

Singapore Institute Of Advanced Medicine Holdings DeferredTaxAndRevenue Related Terms

Singapore Institute Of Advanced Medicine Holdings DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Singapore Institute Of Advanced Medicine Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Singapore Institute Of Advanced Medicine Holdings DeferredTaxAndRevenue Chart

Singapore Institute Of Advanced Medicine Holdings Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Singapore Institute Of Advanced Medicine Holdings Quarterly Data
Jun21 Jun22 Jun23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of S$0.00 Mil mean?
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) has a DeferredTaxAndRevenue of S$0.00 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Singapore Institute Of Advanced Medicine Holdings.
Is Singapore Institute Of Advanced Medicine Holdings' DeferredTaxAndRevenue too high?
Singapore Institute Of Advanced Medicine Holdings' current DeferredTaxAndRevenue is S$0.00 Mil.
How does Singapore Institute Of Advanced Medicine Holdings' DeferredTaxAndRevenue compare to HCA and THC?
Singapore Institute Of Advanced Medicine Holdings' DeferredTaxAndRevenue of S$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Healthcare Providers & Services company?
A good DeferredTaxAndRevenue depends on the Healthcare Providers & Services industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Singapore Institute Of Advanced Medicine Holdings. Singapore Institute Of Advanced Medicine Holdings's current DeferredTaxAndRevenue is S$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singapore Institute Of Advanced Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.04, compared to a current price of S$0.03 — trading 32.5% below its estimated fair value. The current DeferredTaxAndRevenue is S$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Singapore Institute Of Advanced Medicine Holdings (SGX:9G2), the current DeferredTaxAndRevenue is S$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Singapore Institute Of Advanced Medicine Holdings Business Description

Address 1 Biopolis Drive, No. 02-01 Amnios, Singapore, SGP, 138622
Singapore Institute of Advanced Medicine Holdings Ltd is a Singapore-based healthcare service provider comprising a medical center, diagnostic imaging facility, nuclear medicine clinic, and radiation oncology service providing proton and X-ray radiotherapy. Its operating segments are: Medical Diagnostics and Treatments, Radiation Therapy and Medical Oncology Services, and Investment Holding. Medical Diagnostics and Treatments include: cancer-related diagnostics and theranostics treatments, general diagnostics and health screening, and aesthetic services. Radiation Therapy encompasses proton beam therapy, photon radiation therapy, and Medical oncology. The majority of the company's revenue comes from the Medical Diagnostics and Treatments segment.